These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 24668148)
1. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Passot G; You B; Boschetti G; Fontaine J; Isaac S; Decullier E; Maurice C; Vaudoyer D; Gilly FN; Cotte E; Glehen O Ann Surg Oncol; 2014 Aug; 21(8):2608-14. PubMed ID: 24668148 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
3. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129 [TBL] [Abstract][Full Text] [Related]
4. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
5. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [TBL] [Abstract][Full Text] [Related]
6. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638 [TBL] [Abstract][Full Text] [Related]
7. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250 [TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813 [TBL] [Abstract][Full Text] [Related]
9. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Passot G; Vaudoyer D; Cotte E; You B; Isaac S; Noël Gilly F; Mohamed F; Glehen O Ann Surg; 2012 Jul; 256(1):125-9. PubMed ID: 22580942 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139 [TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584 [TBL] [Abstract][Full Text] [Related]
12. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799 [TBL] [Abstract][Full Text] [Related]
13. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745 [TBL] [Abstract][Full Text] [Related]
14. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Goéré D; Souadka A; Faron M; Cloutier AS; Viana B; Honoré C; Dumont F; Elias D Ann Surg Oncol; 2015 Sep; 22(9):2958-64. PubMed ID: 25631064 [TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Teo MC; Tan GH; Tham CK; Lim C; Soo KC Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648 [TBL] [Abstract][Full Text] [Related]
17. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis. Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045 [TBL] [Abstract][Full Text] [Related]
18. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I Trials; 2010 May; 11():62. PubMed ID: 20500867 [TBL] [Abstract][Full Text] [Related]
19. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493 [TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]